{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:32:11Z","timestamp":1725899531800},"publisher-location":"Berlin\/Heidelberg","reference-count":43,"publisher":"Springer-Verlag","isbn-type":[{"type":"print","value":"3540252797"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1007\/3-540-29933-5_9","type":"book-chapter","created":{"date-parts":[[2005,12,26]],"date-time":"2005-12-26T04:49:59Z","timestamp":1135572599000},"page":"147-164","source":"Crossref","is-referenced-by-count":6,"title":["Genotypic Prognostic Markers"],"prefix":"10.1007","author":[{"given":"S.","family":"Stilgenbauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"9_CR1","first-page":"2464","volume":"102","author":"M. Bergmann","year":"2003","unstructured":"Bergmann M, Eichhorst B, Busch R, Hallek M (2003) Elevated thymidine kinase and short lymphocyte doubling time in combination with unfavourable cytogenetics or unmutated IgVH status are strong predictors for high individual risk for rapid disease progression in patients with B-CLL in Binet stage A: an interim report from the CLL1 protocol of the German CLL Study Group (GCLLSG). Blood 102:Abstr 2464","journal-title":"Blood"},{"key":"9_CR2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","volume":"48","author":"J.L. Binet","year":"1981","unstructured":"Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jaquillat C, Boivin P, Lesty C, Duaalt MT, Monconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198","journal-title":"Cancer"},{"key":"9_CR3","first-page":"36","volume":"63","author":"J.C. Byrd","year":"2003","unstructured":"Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Profitt JH, Heerema NA (2003) Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 63:36\u201338","journal-title":"Cancer Res"},{"key":"9_CR4","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"M. Crespo","year":"2003","unstructured":"Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez A, Campo E, Montserrat E (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764\u20131775","journal-title":"N Engl J Med"},{"key":"9_CR5","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"R.N. Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840","journal-title":"Blood"},{"key":"9_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1365-2141.2003.04265.x","volume":"121","author":"G.W. Dewald","year":"2003","unstructured":"Dewald GW, Brockman SR, Paternoster SF, Bone ND, O\u2019Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC, Hanson CA, Pruthi RK, Witzig TE, Call TG, Kay NE (2003) Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 121:287\u2013295","journal-title":"Br J Haematol"},{"key":"9_CR7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000205558","volume":"81","author":"S. Giovanni Di","year":"1989","unstructured":"Di Giovanni S, Valentini G, Carducci P, Giallonardo P (1989) Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol 81:181","journal-title":"Acta Haematol"},{"key":"9_CR8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","volume":"21","author":"G. Dighiero","year":"1998","unstructured":"Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Tavade P, for the French Cooperative Groop on Chronic Lymphocytic Leukemia (1998) Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 21:1506","journal-title":"N Engl J Med"},{"key":"9_CR9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","volume":"85","author":"H. D\u00f6hner","year":"1995","unstructured":"D\u00f6hner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580\u20131589","journal-title":"Blood"},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H. D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Leupolt E, Kr\u00f6ber A, Bullinger L, D\u00f6hner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910\u20131916","journal-title":"N Engl J Med"},{"key":"9_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/sj.leu.2402530","volume":"16","author":"P. Dreger","year":"2002","unstructured":"Dreger P, Montserrat E (2002) Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 16:985\u2013992","journal-title":"Leukemia"},{"key":"9_CR12","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1182\/blood-2003-05-1549","volume":"103","author":"P. Dreger","year":"2004","unstructured":"Dreger P, Stilgenbauer S, Benner A, Ritgen M, Kroeber A, Kneba M, Schmitz N Doehner H (2004) The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 103:2850\u20132858","journal-title":"Blood"},{"key":"9_CR13","first-page":"243","volume":"102","author":"B. Eichhorst","year":"2003","unstructured":"Eichhorst B, Busch R, Hopfinger G, Pasold R, Hensel M, S\u00f6lling U, Siehl S, Steinbrecher C, J\u00e4ger U, Bergmann M, Wendtner CM, Hiddemann W, Emmerich B, Hallek M (2003) Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL). Results of a phase III study (CLL4 protocol) of the German CLL Study Group (GCLLSG). Blood 102:Abstr 243","journal-title":"Blood"},{"key":"9_CR14","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","volume":"82","author":"S. Rouby El","year":"1993","unstructured":"El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression. Blood 82:3452\u20133459","journal-title":"Blood"},{"key":"9_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0145-2126(97)00095-7","volume":"21","author":"C.H. Geisler","year":"1997","unstructured":"Geisler CH, Philip P, Egelund Christensen B, Hou-Jensen K, Tinggaard Peterson N, Myhre Jensen O, Thorling K, Andersen E, Birgens HS, Drivsholm A, Ellegaard J, Larsen JK, Plesner T, Brown P, Kragh Andersen P, M\u00f8rk Hansen M(1997) In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 21:1011\u20131023","journal-title":"Leuk Res"},{"key":"9_CR16","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","volume":"101","author":"P. Ghia","year":"2003","unstructured":"Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, Scielzo C, Caligaris-Cappio F (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101:1262\u20131269","journal-title":"Blood"},{"key":"9_CR17","first-page":"1732","volume":"93","author":"M. Hallek","year":"1999","unstructured":"Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E, Emmerich B (1999) Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93:1732","journal-title":"Blood"},{"key":"9_CR18","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"T.J. Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848","journal-title":"Blood"},{"key":"9_CR19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","volume":"99","author":"T.J. Hamblin","year":"2002","unstructured":"Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023\u20131029","journal-title":"Blood"},{"key":"9_CR20","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.2004.12.133","volume":"22","author":"C. Haslinger","year":"2004","unstructured":"Haslinger C, Schweifer N, Stilgenbauer S, D\u00f6hner H, Lichter P, Kraut N, Stratowa C Abseher R (2004) Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 22:3937\u20133949","journal-title":"J Clin Oncol"},{"key":"9_CR21","doi-asserted-by":"crossref","unstructured":"Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, Kr\u00f6ber A, J\u00e4ger U, Lichter P, D\u00f6hner H, Stilgenbauer S (2005) Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis associated genes. J Clin Oncol (Epub ahead of print)","DOI":"10.1200\/JCO.2005.02.568"},{"key":"9_CR22","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","volume":"194","author":"U. Klein","year":"2001","unstructured":"Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194:1625\u20131638","journal-title":"J Exp Med"},{"key":"9_CR23","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","volume":"100","author":"A. Kr\u00f6ber","year":"2002","unstructured":"Kr\u00f6ber A, Seiler T, Benner A, Bullinger L, Br\u00fcckle E, Lichter P, D\u00f6hner H, Stilgenbauer S (2002) VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410\u20131416","journal-title":"Blood"},{"key":"9_CR24","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2001-11-0066","volume":"100","author":"K. Lin","year":"2002","unstructured":"Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR (2002) Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100:1404\u20131409","journal-title":"Blood"},{"key":"9_CR25","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G. Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Profitt JH, Lucas D, Grever MR, Byrd JC (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278\u20133281","journal-title":"Blood"},{"key":"9_CR26","first-page":"110","volume":"102","author":"K. Maloum","year":"2003","unstructured":"Maloum K, Magnac C, Cazin B, Divine M, Lepretre S, Delmer A, Leporrier M, Jaubert J, Dreyfus B, Guibon O, Dighiero G, Merle-Beral H (2003) Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia predictive value of mutational IgVH gene status for incomplete response and relapse after oral fludarabine phosphate (Fludara oral) and cyclophosphamide in previously untreated CLL patients. Blood 102:Abstr 110","journal-title":"Blood"},{"key":"9_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2004-01-0298","volume":"105","author":"D.W. Milligan","year":"2005","unstructured":"Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD, McConkey C, Child JA, Cunningham D, Morgan GJ, Catovsky D; National Cancer Research Institute Haematological Studies Group (2005) Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105:397\u2013404","journal-title":"Blood"},{"key":"9_CR28","doi-asserted-by":"crossref","unstructured":"Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedu J, Bosch F, Lopez-Guillermo A, Campo E, Sierra J, Montserrat E (2005) Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Oncol (Epub ahead of print)","DOI":"10.1200\/JCO.2005.04.531"},{"key":"9_CR29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2141.1986.tb02969.x","volume":"62","author":"E. Montserrat","year":"1986","unstructured":"Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C (1986) Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62:567","journal-title":"Br J Haematol"},{"key":"9_CR30","first-page":"105","volume":"102","author":"J. Orchard","year":"2003","unstructured":"Orchard J, Davis Z, Ibbotson R, Richards S, Catovsky D, Oscier D (2003) Comparison of ZAP-70, IgVHgene mutational status and CD38 in CLL patients requiring therapy: preliminary report from the UK CLL IV Trial. Blood 102:Abstr 105","journal-title":"Blood"},{"key":"9_CR31","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","volume":"100","author":"D.G. Oscier","year":"2002","unstructured":"Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177\u20131184","journal-title":"Blood"},{"key":"9_CR32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"K.R. Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Paternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219","journal-title":"Blood"},{"key":"9_CR33","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1182\/blood-2002-06-1744","volume":"101","author":"M. Ritgen","year":"2003","unstructured":"Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H, Stuhr A, Kneba M, Dreger P (2003) Unmutated immunoglobulin variable heavy chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 101:2049\u20132053","journal-title":"Blood"},{"key":"9_CR34","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","volume":"104","author":"M. Ritgen","year":"2004","unstructured":"Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C, Raff T, Kr\u00f6ber A, Bunjes D, Schlenk R, Schmitz N, D\u00f6hner H, Kneba M, Dreger P (2004) Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104:2600\u20132602","journal-title":"Blood"},{"key":"9_CR35","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","volume":"194","author":"A. Rosenwald","year":"2001","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639\u20131647","journal-title":"J Exp Med"},{"key":"9_CR36","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V64.3.642.642","volume":"64","author":"C. Rozman","year":"1984","unstructured":"Rozman C, Montserrat E, Rodriguez-Fernandez JM, Ayats R, Vallespi T, Parody R, Rios A, Prados D, Morey M, Gomis F, Alcala A, Gutierrez M, Maldonado J, Gonzales C, Giralt M, Hernandez-Nieto L, Cabrera A, Fernandez-Ranada JM (1984) Bone marrow histologic pattern\u2014the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 64:642","journal-title":"Blood"},{"key":"9_CR37","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1073\/pnas.0304717101","volume":"101","author":"C. Schwaenen","year":"2004","unstructured":"Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B, Kestler HA, Haslinger C, Stilgenbauer S, Dohner H, Bentz M, Lichter P (2004) Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A 101:1039\u20131044","journal-title":"Proc Natl Acad Sci"},{"key":"9_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJM200208083470619","volume":"347","author":"S. Stilgenbauer","year":"2002","unstructured":"Stilgenbauer S, D\u00f6hner H (2002b) Campath-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347:452\u2013453 (letter)","journal-title":"N Engl J Med"},{"key":"9_CR39","first-page":"168","volume":"100","author":"S. Stilgenbauer","year":"2002","unstructured":"Stilgenbauer S, Kr\u00f6ber A, Winkler D, Kienle D, Busch R, Emmerich B, Hallek M, D\u00f6hner H, for the GCLLSG (2002a) VH mutation status and genomic aberrations in the prospective CLL1 trial (Binet-A) of the German CLL Study Group (GCLLSG). Blood 100:168a (Abstr 628)","journal-title":"Blood"},{"key":"9_CR40","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG (2005) Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol (Epub ahead of print)","DOI":"10.1200\/JCO.2005.04.569"},{"key":"9_CR41","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1182\/blood.V99.6.2262","volume":"99","author":"G. Tobin","year":"2002","unstructured":"Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M, Botling J, Enblad G, Sallstrom J, Sundstrom C, Roos G, Rosenquist R (2002) Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99:2262\u20132264","journal-title":"Blood"},{"key":"9_CR42","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1200\/JCO.2003.02.134","volume":"21","author":"Y. Vasconcelos","year":"2003","unstructured":"Vasconcelos Y, Davi F, Levy V, Oppezzo P, Magnac C, Michel A, Yamamoto M, Pritsch O, Merle-Beral H, Maloum K, Ajchenbaum-Cymbalista F, Dighiero G (2003) Binet\u2019s staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 21:3928\u20133932","journal-title":"J Clin Oncol"},{"key":"9_CR43","first-page":"42","volume":"25","author":"J.A. Zwiebel","year":"1998","unstructured":"Zwiebel JA, Cheson BD (1998) Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 25:42","journal-title":"Semin Oncol"}],"container-title":["Current Topics in Microbiology and Immunology","Chronic Lymphocytic Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/3-540-29933-5_9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T22:04:17Z","timestamp":1619561057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/3-540-29933-5_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[null]]},"ISBN":["3540252797"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/3-540-29933-5_9","relation":{},"subject":[]}}